COVID-19 pandemic has caused more than 3 million deaths globally during the past year. The direct attack from SARS-CoV-2 and hyperactivated immune response contribute to the progress and deterioration of COVID-19. After the virus invades, the activation and release of cytokines/chemokines cause "cytokine storm", leading to acute respiratory distress syndrome (ARDS) and multiple organs dysfunction syndrome (MODS). Eliminating virus and blocking cytokines are important checkpoints of COVID-19 therapy, and several agents targeting immunopathology, including interferons, thymosin, glucocorticoids and immunoglobulin, have shown therapeutic effects in severe patients with COVID-19. Herein, we reviewed the practice evidences and concluded that several agents rounding up the immunopathology of COVID-19 may be the alternative approaches under the scenario of the lacking of effective antiviral drugs.
Keyphrases
- sars cov
- acute respiratory distress syndrome
- coronavirus disease
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation
- immune response
- mechanical ventilation
- stem cells
- primary care
- oxidative stress
- case report
- inflammatory response
- bone marrow
- quality improvement
- mesenchymal stem cells
- smoking cessation